JP2021522190A5 - - Google Patents

Info

Publication number
JP2021522190A5
JP2021522190A5 JP2020557325A JP2020557325A JP2021522190A5 JP 2021522190 A5 JP2021522190 A5 JP 2021522190A5 JP 2020557325 A JP2020557325 A JP 2020557325A JP 2020557325 A JP2020557325 A JP 2020557325A JP 2021522190 A5 JP2021522190 A5 JP 2021522190A5
Authority
JP
Japan
Prior art keywords
sequence
cvb1
modified
pharmaceutical composition
cancer
Prior art date
Application number
JP2020557325A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019201192A5 (https=
JP7336791B2 (ja
JP2021522190A (ja
Filing date
Publication date
Priority claimed from CN201810338046.2A external-priority patent/CN110387353B/zh
Application filed filed Critical
Publication of JP2021522190A publication Critical patent/JP2021522190A/ja
Publication of JPWO2019201192A5 publication Critical patent/JPWO2019201192A5/ja
Publication of JP2021522190A5 publication Critical patent/JP2021522190A5/ja
Application granted granted Critical
Publication of JP7336791B2 publication Critical patent/JP7336791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020557325A 2018-04-16 2019-04-15 腫瘍を治療するためのコクサッキーウイルスb群 Active JP7336791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810338046.2 2018-04-16
CN201810338046.2A CN110387353B (zh) 2018-04-16 2018-04-16 一种用于治疗肿瘤的柯萨奇b组病毒
PCT/CN2019/082608 WO2019201192A1 (zh) 2018-04-16 2019-04-15 一种用于治疗肿瘤的柯萨奇b组病毒

Publications (4)

Publication Number Publication Date
JP2021522190A JP2021522190A (ja) 2021-08-30
JPWO2019201192A5 JPWO2019201192A5 (https=) 2022-04-19
JP2021522190A5 true JP2021522190A5 (https=) 2022-04-19
JP7336791B2 JP7336791B2 (ja) 2023-09-01

Family

ID=68240424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020557325A Active JP7336791B2 (ja) 2018-04-16 2019-04-15 腫瘍を治療するためのコクサッキーウイルスb群

Country Status (8)

Country Link
US (1) US20210154249A1 (https=)
EP (1) EP3783100A4 (https=)
JP (1) JP7336791B2 (https=)
KR (1) KR102768669B1 (https=)
CN (1) CN110387353B (https=)
AU (1) AU2019254948B2 (https=)
CA (1) CA3097306A1 (https=)
WO (1) WO2019201192A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114514323A (zh) * 2019-08-05 2022-05-17 复诺健生物科技加拿大有限公司 遗传修饰的肠病毒载体
CN116751288A (zh) * 2020-04-26 2023-09-15 北京万泰生物药业股份有限公司 针对柯萨奇病毒b1型的单克隆抗体及其用途
CN118086228A (zh) * 2022-11-28 2024-05-28 厦门大学 用于治疗肿瘤的柯萨奇b组1型病毒
CN116769733B (zh) * 2023-08-02 2023-11-03 中国医学科学院医学生物学研究所 一种柯萨奇病毒b组4型毒株及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065144B (zh) 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
JP2016500108A (ja) 2012-11-21 2016-01-07 デューク ユニバーシティー ヒトの腫瘍のための腫瘍溶解性ポリオウイルス
JP6396891B2 (ja) * 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
CN103981152B (zh) 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
EP4023233B1 (en) * 2016-09-27 2026-01-07 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
CN109568350B (zh) * 2017-09-29 2023-02-03 厦门大学 一种用于治疗肿瘤的柯萨奇病毒

Similar Documents

Publication Publication Date Title
JP2021522190A5 (https=)
JP6419706B2 (ja) ミニプロモーターカセットを含むレトロウイルスベクター
JP2008545406A5 (https=)
JP2020528890A5 (https=)
JP6961788B2 (ja) プログラム可能な腫瘍溶解性ウイルスワクチン系及びその適用
US20090156796A1 (en) Metastatic colon cancer specific promoter and uses thereof
CN107252438A (zh) 用于治疗癌症的溶瘤腺病毒
WO2008031331A1 (fr) Adénovirus recombinant orienté cible coexprimant p53 et p53aip1 humains
TWI545196B (zh) Reic表現腺病毒載體
CN110387353B (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
Shen et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene
CN104178460B (zh) 一种受转录和转录后双调控的溶瘤腺病毒及其构建方法
Gao et al. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA
JP2020537534A5 (https=)
JPWO2019201192A5 (https=)
Shi et al. Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP producing hepatocarcinoma cell
Durai et al. Principles and applications of gene therapy in colon cancer
WO2016187908A1 (zh) 重组溶瘤腺病毒及其应用
EP2345428B1 (en) Preparation method of prostate tumor-targeted double-regulated oncolytic adenovirus expressing superantigen gene
AU2019359505B2 (en) A method to treat disease using a nucleic acid vector encoding a highly compact multi-input logic gate
CN1242051A (zh) 用于肿瘤治疗和预防的致细胞病变病毒
CN103981185B (zh) 肝癌特异性gp73核心启动子及其筛选构建方法
US20210128653A1 (en) Replication-enhanced oncolytic adenoviruses
EP3822355A1 (en) Anti-tumor composition
RU2814581C1 (ru) Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки